AFT Pharmaceuticals - Poised for international market expansion
AFT continues to focus on expanding its product portfolio and broadening its geographical footprint (including increased investments in its...
311 Views
AFT Pharmaceuticals - US milestone triggers upside and guidance bump
AFT Pharmaceuticals has announced the first sale of its intravenous pain relief medicine, Maxigesic IV, through its US licensing partner, Hikma...
392 Views
AFT Pharmaceuticals - US maiden voyage with Maxigesic IV launch
AFT Pharmaceuticals has announced the launch of Maxigesic IV, an intravenous form of its flagship pain relief prescription medicine, in the US...
209 Views
AFT Pharmaceuticals - Another R&D asset in the bag
AFT Pharmaceuticals has announced the addition of another candidate, HY-091, to its R&D pipeline, for the management of vulvar lichen sclerosus...
267 Views
AFT Pharmaceuticals - R&D pipeline strengthens with new candidate
AFT Pharmaceuticals has bolstered its R&D pipeline with the addition of a new product candidate, HY-090, a locally acting novel molecule,...
697 Views